Boston Scientific Will Offer Alternative To Uterine Morcellation With IoGyn Buy
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific already owns a 28 percent stake in the Silicon Valley start-up, and will now acquire the rest of the firm for $65 million. IoGyn’s 510(k)-cleared uterine surgery tool provides an alternative to power morcellation, which is now being discouraged for use in uterine surgery by FDA.